A Randomized Phase II/III Trial of “Novel Therapeutics” Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), or High-Risk Myelomonocytic Leukemia (CMML), Age 60 or Older”
S1612 is permanently closed to accrual effective Septemeber 1, 2020.
